GlaxoSmithKline remains a leader in obtaining a list of drugs

GlaxoSmithKline maintains its highest position on the global list of pharmaceutical companies, dedicated to providing medicines, vaccines and diagnostics to people in low- and middle-income countries.
's Access to Medicines Index for 2018 - which measures the performance of seven different categories of drugs from the top 20 pharmaceutical companies, such as access to drug management, research and development and pricing - also put Novarma in second place, ahead of Johnson and Johnson and Merck, while Takeda jumped 10 places to fifth place.
"We're happy to be number one and improve our score on the medical index. Phil Thomson, Global President of GlaxoSmithKline, said: 'We welcome the recognition that the largest proportion of research and development pipelines are dedicated to treating priority diseases and establishing a global integrated health research and development division to facilitate collaboration. He continued: "We need to focus more on industry-wide and cross-line collaboration, and we look forward to working with ATMi to address this issue." In addition to the performance of individual companies, further progress must be measured through the collective impact of the joint efforts of the business and other stakeholders. The
also shows that the four major pharmaceutical companies in this area, together with Sanofi (sixth), account for 63 per cent of ongoing priority research and development projects.
" few companies bear most of the priority research and development load shows how fragile the situation is. Even the withdrawal of one of the participants can have a significant impact," said Jayasree Iyer, executive director of the Access to Drugs Foundation. "If more companies join the group, it will bring much-needed flexibility."
index also found that the industry's involvement in such research and development focused on five diseases, half of which were related to malaria, HIV/AIDS, tuberculosis, South American trypanosomiasis and leishmaniasis.
analysis shows that most priority research and development projects are working with public sector research institutions, but some companies are developing priority products that do not have such conveniences, such as Merck's work in schistosomiasis detection and treatment.
" this proves that when society agrees to priorities, it clearly helps to focus industry efforts," said Danny Edwards, head of research at the index.
" our analysis found this not only in research and development, but also in the actions of companies that have access to medicines once they enter the market. In short, more companies will be involved if there is a call to action or a donation, especially in areas with low commercial potential. (This net special draft)